These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


147 related items for PubMed ID: 23054618

  • 1. Immunohistochemical analysis of thymic carcinoma focusing on the possibility of molecular targeted and hormonal therapies.
    Omatsu M, Kunimura T, Mikogami T, Hamatani S, Shiokawa A, Masunaga A, Kitami A, Suzuki T, Kadokura M, Morohoshi T.
    Gen Thorac Cardiovasc Surg; 2012 Dec; 60(12):803-10. PubMed ID: 23054618
    [Abstract] [Full Text] [Related]

  • 2. Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study.
    Aisner SC, Dahlberg S, Hameed MR, Ettinger DS, Schiller JH, Johnson DH, Aisner J, Loehrer PJ.
    J Thorac Oncol; 2010 Jun; 5(6):885-92. PubMed ID: 20421818
    [Abstract] [Full Text] [Related]

  • 3. Steroid receptor expression in thymomas and thymic carcinomas.
    Mimae T, Tsuta K, Takahashi F, Yoshida A, Kondo T, Murakami Y, Okada M, Takeuchi M, Asamura H, Tsuda H.
    Cancer; 2011 Oct 01; 117(19):4396-405. PubMed ID: 21437890
    [Abstract] [Full Text] [Related]

  • 4. Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours.
    Pan CC, Chen PC, Wang LS, Lee JY, Chiang H.
    Histopathology; 2003 Aug 01; 43(2):165-72. PubMed ID: 12877732
    [Abstract] [Full Text] [Related]

  • 5. HER family receptor and ligand status in thymic carcinoma.
    Weissferdt A, Lin H, Woods D, Tang X, Fujimoto J, Wistuba II, Moran CA.
    Lung Cancer; 2012 Sep 01; 77(3):515-21. PubMed ID: 22726920
    [Abstract] [Full Text] [Related]

  • 6. Clinicopathological features of metaplastic breast carcinoma.
    Hasdemir OA, Tokgöz S, Köybaşıoğlu F, Karabacak H, Yücesoy C, İmamoğlu Gİ.
    Adv Clin Exp Med; 2018 Apr 01; 27(4):509-513. PubMed ID: 29558027
    [Abstract] [Full Text] [Related]

  • 7. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
    Pan CC, Chen PC, Chou TY, Chiang H.
    Hum Pathol; 2003 Nov 01; 34(11):1155-62. PubMed ID: 14652817
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
    Tiseo M, Damato A, Longo L, Barbieri F, Bertolini F, Stefani A, Migaldi M, Gnetti L, Camisa R, Bordi P, Buti S, Rossi G.
    Lung Cancer; 2017 Feb 01; 104():24-30. PubMed ID: 28212996
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma.
    Kaira K, Murakami H, Serizawa M, Koh Y, Abe M, Ohde Y, Takahashi T, Kondo H, Nakajima T, Yamamoto N.
    Virchows Arch; 2011 May 01; 458(5):615-20. PubMed ID: 21253760
    [Abstract] [Full Text] [Related]

  • 12. Prognostic markers in triple-negative breast cancer.
    Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO.
    Cancer; 2007 Jan 01; 109(1):25-32. PubMed ID: 17146782
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma.
    Owen D, Chu B, Lehman AM, Annamalai L, Yearley JH, Shilo K, Otterson GA.
    J Thorac Oncol; 2018 Aug 01; 13(8):1204-1212. PubMed ID: 29702286
    [Abstract] [Full Text] [Related]

  • 15. Insulin-like growth factor-1 receptor expression in thymic malignancies.
    Girard N, Teruya-Feldstein J, Payabyab EC, Riely GJ, Rusch VW, Kris MG, Zakowski MF.
    J Thorac Oncol; 2010 Sep 01; 5(9):1439-46. PubMed ID: 20736806
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas.
    Meister M, Schirmacher P, Dienemann H, Mechtersheimer G, Schnabel PA, Kern MA, Herpel E, Xu EC, Muley T, Thomas M, Rieker RJ.
    Cancer Lett; 2007 Apr 18; 248(2):186-91. PubMed ID: 16919868
    [Abstract] [Full Text] [Related]

  • 18. L-Type Amino Acid Transporter 1 Immunoreactivity as a Possible Diagnostic and Prognostic Marker of Thymic Carcinoma.
    Maeda S, Nakazato Y, Hayashi K, Nishihira M, Inoue T, Araki O, Karube Y, Kobayashi S, Chida M.
    Tohoku J Exp Med; 2018 Nov 18; 246(3):167-174. PubMed ID: 30449824
    [Abstract] [Full Text] [Related]

  • 19. Thymic carcinoma arising in thymoma is associated with alterations in immunohistochemical profile.
    Kuo TT, Chan JK.
    Am J Surg Pathol; 1998 Dec 18; 22(12):1474-81. PubMed ID: 9850173
    [Abstract] [Full Text] [Related]

  • 20. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment.
    Wenhui Z, Shuo L, Dabei T, Ying P, Zhipeng W, Lei Z, Xiaohui H, Jingshu G, Hongtao S, Qingyuan Z.
    Eur J Endocrinol; 2014 Oct 18; 171(4):527-33. PubMed ID: 25069458
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 8.